In May 2019, alpelisib, a novel first-in-class oral small molecule PIK3CA-isoform–specific inhibitor [7], received Food and Drug Administration (FDA) approval for the treatment of metastatic ER+ breast cancer harboring PIK3CA mutations following progression of disease on or after treatment with ET. This evidence concerns the gene ESR1 and breast carcinoma.